SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001; 15: 167.
  • 2
    Yip SY. The prevalence of psoriasis in the Mongoloid race. J Am Acad Dermatol 1984; 10: 9658.
  • 3
    Tao X, Lipsky PE. The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Complementary and alternative therapies for rheumatic diseases II. Rheum Dis Clin North Am 2000; 26: 2950.
  • 4
    Gutian Hospital and Beisha Hospital FP. Report on the therapeutic effect of the herbal medicine Tripterygium wilfordii Hook F on reactive status of leprosy [in Chinese]. Pi Fu Bing Fang Zhi Tong Xun 1972; 2: 2930.
  • 5
    Chen BJ. Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma 2001; 42: 25365.
  • 6
    Asano K, Matsuishi J, Yu Y, Kasahara T, Hisamitsu T. Suppressive effects of Tripterygium wilfordii Hook F, a traditional Chinese medicine, on collagen arthritis in mice. Immunopharmacol 1998; 39: 11726.
  • 7
    Chang ML, Yang LL, Chang DM, Kuo SY, Chu SJ. The influence of Chinese traditional medicine on the production and activity of interleukin 1 (IL-1) [in Chinese]. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 1993; 26: 1524.
  • 8
    Chang DM, Chang WY, Kuo SY, Chang ML. The effects of traditional antirheumatic herbal medicines on immune response cells. J Rheumatol 1997; 24: 43641.
  • 9
    Tao X, Schulze-Koops H, Ma L, Cai J, Mao Y, Lipsky PE. Effects of Tripterygium wilfordii Hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. Arthritis Rheum 1998; 41: 1308.
  • 10
    Ho LJ, Chang DM, Chang ML, Kuo SY, Lai JH. Mechanism of immunosuppression of the antirheumatic herb TWHf in human T cells. J Rheumatol 1999; 26: 1424.
  • 11
    Wu Y, Wang Y, Zhong C, Li Y, Li X, Sun B. The suppressive effect of triptolide on experimental autoimmune uveoretinitis by down-regulating Th1-type response. Int Immunopharmacol 2003; 3: 145765.
  • 12
    Kupchan SM, Court WA, Dailey RG Jr, Gilmore CJ, Bryan RF. Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J Am Chem Soc 1972; 94: 71945.
  • 13
    Chen BJ, Chen Y, Cui X, Fidler JM, Chao NJ. Mechanisms of tolerance induced by PG490-88 in a bone marrow transplantation model. Transplantation 2002; 73: 11521.
  • 14
    Liu Q, Chen T, Chen H, Zhang M, Li N, Lu Z, Ma P, Cao X. Triptolide (PG-490) induces apoptosis of dendritic cells through sequential p38 MAP kinase phosphorylation and caspase 3 activation. Biochem Biophys Res Commun 2004; 319: 9806.
  • 15
    Jiang XH, Wong BC, Lin MC, Zhu GH, Kung HF, Jiang SH, Yang D, Lam SK. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene 2001; 20: 800918.
  • 16
    Wang X, Matta R, Shen G, Nelin LD, Pei D, Liu Y. Mechanism of triptolide-induced apoptosis: effect on caspase activation and Bid cleavage and essentiality of the hydroxyl group of triptolide. J Mol Med 2006; 84: 40515.
  • 17
    Tang ZL. New development in clinical application of Tripierygium wilfordii Hook F [in Chinese]. Papers series of the Fourth National Academic Conference of Tripierygium wilfordii Hook F: 2004.
  • 18
    Tao XL, Sun Y, Dong Y. A double-blind, controlled trial of Tripterygium wilfordii glycosides in the treatment of rheumatoid arthritis. Arthritis Rheum 1987; 30: 599.
  • 19
    Yu DY. Clinical observation of 144 cases of rheumatoid arthritis treated with glycoside of radix Tripterygium wilfordii [in Chinese]. J Tradit Chin Med 1983; 3: 1259.
  • 20
    Huang CF, Wu CB, Shen ZK. Study on the treatment of rheumatoid arthritis with polyglycosides of Tripterygium wilfordii Hook-a randomized, controlled, cross-over clinical trial [in Chinese]. Third Annual National Meeting of Rheumatology (Chinese): 2003.
  • 21
    RA Cooperative Group. Clinical trial of Tripterygium wilfordii Hook in the treatment of 31 patients with rheumatoid arthritis [in Chinese]. Wuhan Yi Xue Bao 1977; 6: 513.
  • 22
    Su DF, Li RL, Sun YJ. Report of 270 patients with rheumatoid arthritis treated with ethyl acetate extract of Tripterygium wilfordii Hook F. [in Chinese]. Zhong Yao Yao Li Yu Lin Chuang 1989; 5: 402.
  • 23
    Li ZM, Zheng CS. Observation on treatment of systemic lupus erythematosus with extract of Tripterygium wilfordii Hook [in Chinese]. J New Chin Med 1982; 12: 224.
  • 24
    Liao WQ. Observations on the therapeutic effect of Tripterygium wilfordii Hook F on systemic lupus ethythematosus [in Chinese]. Pi Fu Bing Fang Zhi Yan Jiu Tong Xun 1980; 9: 145.
  • 25
    Xue ZY. Treating 103 cases of SLE with Tripterygium wilfordii Hook F [in Chinese]. Chin J Dermatol 1982; 15: 1413.
  • 26
    Xue GY, Xue JH, Tang YC. Treatment of 21 patients with SLE with Tripterygium wilfordii Hook [in Chinese]. Chin J Dermatol 1984; 17: 2013.
  • 27
    Su LD, You JC. Comparison of efficacy between Tripterygium wilfordii Hook and cochicine in the treatment of systemic sclerosis [in Chinese]. Third Annual National Meeting of Rheumatology (Chinese): 1988.
  • 28
    Bei RX, Liu H, Wang XC. Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis and ankylosing spondylitis [in Chinese]. Chin J Orthop 1988; 8: 20913.
  • 29
    Guo JL, Gao ZG, Zan AC. Treatment of rheumatoid arthritis and ankylosing spondylitis with Tripterygium wilfordii Hook F: 2-5 year follow-up [in Chinese]. Chin J Orthop 1984; 4: 1337.
  • 30
    Fan ZH. Analysis of the therapeutic effect of Tripterygium wilfordii Hook on 52 patients with psoriasis [in Chinese]. Acta Acad Med Nanjing 1984; 14: 4513.
  • 31
    Xu WY, Zheng JR, Lu XY. Tripterygium in dermatologic therapy. Int J Dermatol 1985; 24: 1527.
  • 32
    Xie DF, Shen JS, Fei JF. Experience in the treatment of Behcet's disease with polyglycosides of Tripterygium wilfordii Hook f [in Chinese]. Chin J Integr Med 1983; 3: 34950.
  • 33
    Wan L, Zhao RF, Zhou W, Yuan NM. Clinical analysis of 50 cases of Behcet disease treated by thalidomide combined with Tripterygium glycosides [in Chinese]. J Pract Stomatol 2006; 22: 65961.
  • 34
    Luo HP. Treatment on 10 cases of Behcet's disease using decoction of Tripterygium wilfordii [in Chinese]. Jiujiang Med J 2002; 17: 41.
  • 35
    Sun Q, Qiu JF, Cai ZH, Shen MJ. Tripterygium wilfordii treatment of polymyositis and dermatomyositis-preliminary change of creatase [in Chinese]. J Chin Physician 1998; 3: 54.
  • 36
    Bai HT, Yang DS, Zheng YJ. Effect of Triptergium glycosides on children with allergic purpura [in Chinese]. J Xinxiang Med Coll 2002; 19: 2823.
  • 37
    Dong Z, Jiao YQ, Lu SG. The use of double-dosed Tripterygium polyglucoside in treating Henoch-Schonlein purpura [in Chinese]. Acta Acad Med Xuzhou 2003; 23: 3346.
  • 38
    Feng B. Observation on the effect of polyglycosides of Tripterygium wilfordii Hook (T2) in 50 cases of leprosy reactive status [in Chinese]. Clin J Dermatol 1985; 4: 211.
  • 39
    Lei Gong Teng Cooperative Research Group of Fujian and Jiangsu Provinces. Clinical observation on Chinese herb Lei Gong Teng in treatment of leprosy reaction [in Chinese]. Acta Acad Med Sin 1979; 1: 724.
  • 40
    Wu YZ. Treatment of neuralgia of lepra reactive status with polyglycosides of Tripterygium wilfordii Hook F (T2) [in Chinese]. Chin J Dermatol 1986; 19: 2179.
  • 41
    Mou LP. The clinical observation of chronic lymphatic thyroiditis with treatment of Tripterygium Witfondii Hooh F. [in Chinese]. J Bengbu Med Coll 2000; 25: 2545.
  • 42
    Jiang X. Clinical observations on the use of the Chinese herb Tripterygium wilfordii Hook for the treatment of nephrotic syndrome. Pediatr Nephrol 1994; 8: 3434.
  • 43
    Xu G, Tu W, Jiang D, Xu C. Tripterygium wilfordii Hook F treatment for idiopathic refractory nephrotic syndrome in adults: a meta-analysis. Nephron Clin Pract 2009; 111: c223c228.
  • 44
    Yang FY, Wei CY, Li CY. A controlled study on Tripterygium glycosides for treating IgA nephropathy patients who presented with non-nephrofic syndrome [in Chinese]. Chin J Gen Pract 2008; 6: 11389.
  • 45
    Xie T, Zhong YX, Mai WM, Huang PP. Clinic research on Tripterygium glycosides for treating IgA nephropathy [in Chinese]. Chin J Postgrad Med 2008; 31: 356.
  • 46
    Li X, Hao J. Clinical Observation on Urokinase Combined with Tripterygium Wilfordii Polyglycoside For IgA Nephropathy [in chinese]. Appl J Gen Pract 2006; 4: 4101.
  • 47
    Ma WH, Guo XQ, Wei ZH. Effect of Tripterygium Glycosides with Prednisone in Treating Henoch-Schonlein Purpura Nephritis [in chinese]. J Appl Clin Pediatr 2007; 22: 13446.
  • 48
    Li QH, Hu ZX, Huang MG. Clinical observation on Huang Kui capsule combined with Tripterygium wilfordii polyglycoside for chronic glomerulonephritis [in Chinese]. Mod J Integr Tradit Chin West Med 2005; 14: 142930.
  • 49
    Zhang CQ, Zhang F, Feng J, Li WB, Yan XN, Hu G. Effects of polyglycoside of Tripterygium wilfordii Hook F on NF-kappa B expression in HaCa Tcells [in Chinese]. Shanxi Med J 2008; 37: 7946.
  • 50
    T2 Study Group of Jiangsu Province. Summary on the clinical trials of T2 in the treatment of 554 patients with various diseases [in Chinese]. Ann Chin Acad Med Sin 1982; 3: 35.
  • 51
    Yuan XY, Shao KW, Zhang JT. Treatment of diffusive neurodermatitis with Tripterygium wilfordii Hook [in Chinese]. Fujian Med J 1987; 9: 5.
  • 52
    Wang YH, Ye H, Yu LX, Yang ZX. The effect of Tripterygium wilfordii combined with corticosteroid in the treatment of pemphigus and pemphigoid [in Chinese]. Central China Med J 2001; 25: 656.
  • 53
    Tao X, Cush JJ, Garret M, Lipsky PE. A phase I study of ethyl acetate extract of the Chinese antirheumatic herb Tripterygium wilfordii Hook F in rheumatoid arthritis. J Rheumatol 2001; 28: 21607.
  • 54
    Cibere J, Deng Z, Lin Y, Ou R, He Y, Wang Z, Thorne A, Lehman AJ, Tsang IK, Esdaile JM. A randomized double blind, placebo controlled trial of topical Tripterygium wilfordii in rheumatoid arthritis: reanalysis using logistic regression analysis. J Rheumatol 2003; 30: 4657.
  • 55
    Tao X, Younger J, Fan FZ, Wang B, Lipsky PE. Benefit of an extract of Tripterygium wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2002; 46: 173543.
  • 56
    He QB. Effects of Tripterygium wilfordii polyglycosidium combined with azithromycin on the treatment of psoriasis vulgaris in 45 cases [in Chinese]. J Zhengzhou Univ (Med Sci) 2004; 39: 8967.
  • 57
    Hang SY. Clinic observation of Tripterygium wilfordii combined with Di Yin Pian on the treatment of progressive stage psoriasis vulgaris [in Chinese]. South China J Dermatol-Venerol 2001; 8: 2467.
  • 58
    Ma YB, Cheng SC, Wnag XY. A double-blind research on the therapeutic effect of Tripterygium wilfordii Hook F on progressive stage psoriasis vulgaris [in Chinese]. Chin J Convalescent Med 2000; 9: 335.
  • 59
    Yang XY, Liu XQ, Li HZ, Lin L, Chen K. Therapeutic effect of Tripterygium wilfordii Hook F combined with erythromycin and glycyrrhizin on 152 cases of psoriasis vulgaris [in Chinese]. Chin J Dermatol-Venereol 2000; 14: 1689.
  • 60
    Chen JZ. Clinic observation of Tripterygium wilfordii combined with Di Yin Pian on the treatment of psoriasis in 87 patients[in chinese]. J Henan Med Univ 2000; 35: 1123.
  • 61
    Zhang FR, Tian RM, Ma SY, Wang XY, Yu ML, Shi ZX. Treatment of active psoriasis vulgaris with Tripterygium wilfordii – double blind controlled triaI [in Chinese]. Clin J Dermatol 1999; 28: 323.
  • 62
    Feng PH, Zhang Y. Clinic observation of Tripterygium wilfordii combined with Di Yin Pian on the treatment of psoriasis [in Chinese]. J Community Med 2004; 2: 85.
  • 63
    Huang YZ, Huang FR, Ma DX. Observation on clinical effect of Tripterygium wilfordii polyglycosidium combined with Di Yin Pian on the treatment of psoriasis vulgaris in 52 cases [in Chinese]. Chin J Curr Tradit West Med 2004; 2: 2389.
  • 64
    Lu GQ, Yin XD, Lu SG. Tripterygium wilfordii combined with Bimolane on the treatment of psoriasis in 98 cases [in Chinese]. J Dermatol Venereol 2003; 25: 2930.
  • 65
    Shen YZ, Wang JQ, Xu XM. Observations on the therapeutic effect of decotion of Tripterygium wilfordii Hook F on psoriasis vulgaris [in Chinese]. Mod J Integr Tradit Chin West Med 2008; 17: 35978.
  • 66
    Zhan QX, Xu XM. Efficiency of Tripterygiuln wilfordii on treating psoriasis – A systematic review. Chin J Dermatovenereol Integr Tradit West Med 2007; 6: 1926.
  • 67
    Wong KF, Chan JK, Chan KL, Tam P, Yang D, Fan ST, Luk JM. Immunochemical characterization of the functional constituents of Tripterygium wilfordii contributing to its anti-inflammatory property. Clin Exp Pharmacol Physiol 2008; 35: 559.
  • 68
    Lu Y, Fukuda K, Nakamura Y, Kimura K, Kumagai N, Nishida T. Inhibitory effect of triptolide on chemokine expression induced by proinflammatory cytokines in human corneal fibroblasts. Invest Ophthalmol Vis Sci 2005; 46: 234652.
  • 69
    Lin N, Liu C, Xiao C, Jia H, Imada K, Wu H, Ito A. Triptolide, a diterpenoid triepoxide, suppresses inflammation and cartilage destruction in collagen-induced arthritis mice. Biochem Pharmacol 2007; 73: 13646.
  • 70
    Gong Y, Xue B, Jiao J, Jing L, Wang X. Triptolide inhibits COX-2 expression and PGE2 release by suppressing the activity of NF-kappaB and JNK in LPS-treated microglia. J Neurochem 2008; 107: 77988.
  • 71
    Kim YH, Lee SH, Lee JY, Choi SW, Park JW, Kwon TK. Triptolide inhibits murine-inducible nitric oxide synthase expression by down-regulating lipopolysaccharide-induced activity of nuclear factor-kappa B and c-Jun NH2-terminal kinase. Eur J Pharmacol 2004; 494: 19.
  • 72
    Liou JT, Chen ZY, Ho LJ, Yang SP, Chang DM, Liang CC, Lai JH. Differential effects of triptolide and tetrandrine on activation of COX-2, NF-kappaB, and AP-1 and virus production in dengue virus-infected human lung cells. Eur J Pharmacol 2008; 589: 28898.
  • 73
    Krakauer T, Chen X, Howard OM, Young HA. Triptolide attenuates endotoxin- and staphylococcal exotoxin-induced T-cell proliferation and production of cytokines and chemokines. Immunopharmacol Immunotoxicol 2005; 27: 5366.
  • 74
    Qiu D, Zhao G, Aoki Y, Shi L, Uyei A, Nazarian S, Ng JC, Kao PN. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem 1999; 274: 1344350.
  • 75
    Wang Y, Jia L, Wu CY. Triptolide inhibits the differentiation of Th17 cells and suppresses collagen-induced arthritis. Scand J Immunol 2008; 68: 38390.
  • 76
    Tao X, Davis LS, Lipsky PE. Effect of an extract of the Chinese herbal remedy Tripterygium wilfordii Hook F on human immune responsiveness. Arthritis Rheum 1991; 34: 127481.
  • 77
    Zhu KJ, Shen QY, Cheng H, Mao XH, Lao LM, Hao GL. Triptolide affects the differentiation, maturation and function of human dendritic cells. Int Immunopharmacol 2005; 5: 141526.
  • 78
    Chen X, Murakami T, Oppenheim JJ, Howard OM. Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic-cell maturation and trafficking. Blood 2005; 106: 240916.
  • 79
    Liu HK, Perrier S, Lipina C, Finlay D, McLauchlan H, Hastie CJ, Hundal HS, Sutherland C. Functional characterisation of the regulation of CAAT enhancer binding protein alpha by GSK-3 phosphorylation of threonines 222/226. BMC Mol Biol 2006; 7: 14.
  • 80
    Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372: 146372.
  • 81
    Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med 2005; 11: 438.
  • 82
    Shear NH, Prinz J, Papp K, Langley RG, Gulliver WP. Targeting the interleukin-12/23 cytokine family in the treatment of psoriatic disease. J Cutan Med Surg 2008; 12: (Suppl. 1): S110.
  • 83
    Liu J, Wu QL, Feng YH, Wang YF, Li XY, Zuo JP. Triptolide suppresses CD80 and CD86 expressions and IL-12 production in THP-1 cells. Acta Pharmacol Sin 2005; 26: 2237.
  • 84
    Liu Y, Chen Y, Liu FQ, Lamb JR, Tam PK. Combined treatment with triptolide and rapamycin prolongs graft survival in a mouse model of cardiac transplantation. Transpl Int 2008; 21: 48394.
  • 85
    Zhang Y, Ma X. Triptolide inhibits IL-12/IL-23 expression in APCs via CCAAT/enhancer-binding protein alpha. J Immunol 2010; 184: 386677.
  • 86
    Premkumar V, Dey M, Dorn R, Raskin I. MyD88-dependent and independent pathways of toll-like receptors are engaged in biological activity of triptolide in ligand-stimulated macrophages. BMC Chem Biol 2010; 10: 3.
  • 87
    Liu YJ, Yang ZB, Lv N, Li JY. Effects of Triperygium wiIfordii ointment on expression of Intercelluar adhesion molecule-1 and matrix metallo-proteinase-9 in psoriatic lesion.[in Chinese]. Chin J Dermatovenereol Integr Tradit West Med 2007; 6: 2135.
  • 88
    Xiao T, Guo YJ, Wu J, Wu J, Wang YK, He CD, Chen HD. Effect of immunosuppressants on secretion of CXCL11/I-TAC by HaCaT cells. J China Med Univ 2008; 37: 168.
  • 89
    Vispe S, DeVries L, Creancier L, Besse J, Breand S, Hobson DJ, Svejstrup JQ, Annereau JP, Cussac D, Dumontet C, Guilbaud N, Barret JM, Bailly C. Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Mol Cancer Ther 2009; 8: 278090.
  • 90
    Pan J. RNA polymerase – an important molecular target of triptolide in cancer cells. Cancer Lett 2010; 292: 14952.
  • 91
    Wei YS, Adachi I. Inhibitory effect of triptolide on colony formation of breast and stomach cancer cell lines. Zhongguo Yao Li Xue Bao 1991; 12: 40610.
  • 92
    Shao F, Wang G, Xie H, Zhu X, Sun J, A J. Pharmacokinetic study of triptolide, a constituent of immunosuppressive Chinese herb medicine, in rats. Biol Pharm Bull 2007; 30: 7027.
  • 93
    Zheng JR, Xu LF, Ma L, Wang DH, Gao JW. Studies on pharmacological actions of total glycosides in Tripterygium wilfordii [in Chinese]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 1983; 5: 18.
  • 94
    Wang ZF, Zhang YH, Huang GZ. An experimental, pathological study of subchronic intoxication of ethyl acetate extract of Tripterygium wilfordii Hook [in Chinese]. J TongJi Med Coll 1991; 20: 24750.
  • 95
    Cheng YL, Ye JR, Lin DJ. [Some toxicities of triptolide in mice and dogs (author's translation)]. Zhongguo Yao Li Xue Bao 1981; 2: 702.
  • 96
    Li H, Cheng QR, Dong DC. Observation on clinical effect on treatment of IgA nephropathy with Tripterygium wilfordii Hook [in Chinese]. Shanghai Yi Xue 2010; 16: 2234.
  • 97
    Liu WZ, Chen RX. Studies on the efficacy of polyglycosides of Tripterygium wilfordii Hook in the treatment of nephritis [in Chinese]. Shanghai Zhong Yi Za Zhi 1990; 2: 5.
  • 98
    Pan YR. Treatment of purpura nephritis with Tripterygium wilfordii Hook F [in Chinese]. Acta Acad Med Sin 1987; 9: 24.
  • 99
    Wang QW, Li LS, Zhang JH. Clinical studies of treatment of idiopathic IgA nephropathy with Tripterygium wilfordii Hook F [in Chinese]. Jiangsu Med 1991; 1: 79.
  • 100
    Su DF, Li RL, Sun YJ. Report of 270 patients with rheumatoid arthritis treated with ethyl acetate extract of Tripterygium wilfordii Hook F [in Chinese]. Pharmacol Clin Tradit Chin Med 1989; 5: 402.
  • 101
    Chan MA, Kohlmeier JE, Branden M, Jung M, Benedict SH. Triptolide is more effective in preventing T cell proliferation and interferon-gamma production than is FK506. Phytother Res 1999; 13: 4647.
  • 102
    Qiu D, Kao PN. Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook F. Drugs R D 2003; 4: 118.
  • 103
    Jiang L, Zhao N, Ni L. Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 2002; 23: 2137.
  • 104
    Zhou J, Zhu Q, Yang X. Clinical observation of side effects of Tripterygium preparation [in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1999; 19: 779.
  • 105
    Gu CX. Cause of amenorrhea after treatment with Tripterygium wilfordii F [in Chinese]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 1989; 11: 1513.
  • 106
    Qian SZ. Tripterygium wilfordii, a Chinese herb effective in male fertility regulation. Contraception 1987; 36: 33545.
  • 107
    Zhen QS, Ye X, Wei ZJ. Recent progress in research on Tripterygium: a male antifertility plant. Contraception 1995; 51: 1219.
  • 108
    Meikle AW. Endocrine Replacement Therapy in Clinical Practice (Contemporary Endocrinology). New York, NY: Humana Press, 2003.
  • 109
    Chou WC, Wu CC, Yang PC, Lee YT. Hypovolemic shock and mortality after ingestion of Tripterygium wilfordii hook F.: a case report. Int J Cardiol 1995; 49: 1737.
  • 110
    Pyatt DW, Yang Y, Mehos B, Le A, Stillman W, Irons RD. Hematotoxicity of the chinese herbal medicine Tripterygium wilfordii Hook F in CD34-positive human bone marrow cells. Mol Pharmacol 2000; 57: 5128.
  • 111
    Chan WY, Ng TB. Adverse effect of Tripterygium wilfordii extract on mouse embryonic development. Contraception 1995; 51: 6571.
  • 112
    Takei A, Nagashima G, Suzuki R, Hokaku H, Takahashi M, Miyo T, Asai J, Sanada Y, Fujimoto T. Meningoencephalocele associated with Tripterygium wilfordii treatment. Pediatr Neurosurg 1997; 27: 458.
  • 113
    Guo JL, Yuan SX, Wang XC, Xu SX, LI DD. Tripterygium wilfordii Hook F in rheumatoid arthritis and ankylosing spondylitis. Preliminary report. Chin Med J (Engl) 1981; 94: 40512.
  • 114
    Zhu TZ. Explore the causes of death in 90 cases with intoxication of Tripterygium wilfordii Hook [in Chinese]. Beijing Zhong Yi 1995; 2: 357.
  • 115
    Su D, Song Y, Li R. Comparative clinical study of rheumatoid arthritis treated by triptolide and an ethyl acetate extract of Tripterygium wilfordii [in Chinese]. Zhong Xi Yi Jie He Za Zhi 1990; 10: 1446. 131.
  • 116
    Zhang F, Li YC. Progress in structure modification of triptolide[in chinese]. Yao Xue Xue Bao 2004; 39: 85764.
  • 117
    Krishna G, Liu K, Shigemitsu H, Gao M, Raffin TA, Rosen GD. PG490-88, a derivative of triptolide, blocks bleomycin-induced lung fibrosis. Am J Pathol 2001; 158: 9971004.
  • 118
    Pan F, Fisniku O, Wynn C, Erickson LM, Crews G, Jang MS, Sudo Y, Tamura K, Kobayashi M, Benediktsson H, Jiang H. PG490-88, a new immunosuppressant, effectively prevents acute and chronic rejection in rat renal allografts. Transplant Proc 2005; 37: 1346.
  • 119
    Kiviharju TM, Lecane PS, Sellers RG, Peehl DM. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res 2002; 8: 266674.
  • 120
    Harousseau JL, Dombret H, Pigneux A, Michallet M, Brandely M. Phase I study of F60008, a triptolide derivative, in patients with refractory or relapsing acute leukemias. 13th Congress of the European Hematology Association (EHA); 2008: 2008.
  • 121
    Kitzen JJ, de Jonge MJ, Lamers CH, Eskens FA, van der BD, van Doorn L, Ter Steeg J, Brandely M, Puozzo CH, Verweij J. Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer 2009; 45: 176472.
  • 122
    Ren YX, Zhou R, Tang W, Wang WH, Li YC, Yang YF, Zuo JP. (5R)-5-hydroxytriptolide (LLDT-8) protects against bleomycin-induced lung fibrosis in mice. Acta Pharmacol Sin 2007; 28: 51825.
  • 123
    Zhou R, Wang JX, Tang W, He PL, Yang YF, Li YC, Li XY, Zuo JP. (5R)-5-hydroxytriptolide inhibits IFN-gamma-related signaling. Acta Pharmacol Sin 2006; 27: 161621.
  • 124
    Zhou R, Tang W, He PL, Yang YF, Li YC, Zuo JP. (5R)-5-hydroxytriptolide inhibits the immune response of human peripheral blood mononuclear cells. Int Immunopharmacol 2009; 9: 639.
  • 125
    Shao F, Wang GJ, Sun JG, Xie HT, Zhang R, Zhu XY. Pharmacokinetics of triptolide in Beagle dogs [in Chinese]. Yao Xue Xue Bao 2007; 42: 615.